文献速递胸部肿瘤

阿来替尼用于ALK重排阳性且体能状态差的非小细胞肺癌患者(九州肺癌研究组1401)

Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).
PubMed 文献 · J Thorac Oncol · 2017-02-24

这项II期研究纳入18例晚期ALK重排阳性且PS 2-4的非小细胞肺癌患者,口服阿来替尼300 mg每日两次。客观缓解率为72.2%(90%CI 52.9-85.8%),PS改善率为83.3%(90%CI 64.8-93.1%,P<0.0001),中位无进展生存期为10.1个月,毒性轻微。结论认为阿来替尼是该类患者的一种治疗选择。

要点

  • 18例PS 2-4的ALK阳性NSCLC患者接受阿来替尼300 mg每日两次口服。
  • 客观缓解率72.2%(90%CI 52.9-85.8%),PS 2与PS≥3组无显著差异(58.3%对100%,P=0.114)。
  • PS改善率83.3%(90%CI 64.8-93.1%,P<0.0001),中位无进展生存期10.1个月。

核心结论

  • 阿来替尼是ALK重排阳性且体能状态差的非小细胞肺癌患者的一种治疗选择。

研究设计与样本

  • II期研究,2014年9月至2015年12月入组18例晚期ALK重排阳性且PS 2-4的非小细胞肺癌患者,口服阿来替尼300 mg每日两次。

主要发现

  • 18例中PS 2、3、4者分别为12例、5例、1例,4例既往接受过克唑替尼治疗。
  • 客观缓解率为72.2%(90%CI 52.9-85.8%)。
  • PS 2组与PS 3或更高组的客观缓解率分别为58.3%和100%,两组无显著差异(P=0.114)。
  • PS改善率为83.3%(90%CI 64.8-93.1%,P<0.0001),改善至PS 0或1的频率为72.2%。
  • 中位无进展生存期为10.1个月,毒性轻微,3级或以上不良事件频率低,无需因毒性减量或停药。

临床怎么用

  • 原文结论认为阿来替尼是ALK重排阳性且体能状态差的非小细胞肺癌患者的一种治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alectinib has shown marked efficacy and safety in patients with anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement-positive NSCLC and a good performance status (PS). It has remained unclear whether alectinib might also be beneficial for such patients with a poor PS. METHODS: Eligible patients with advanced ALK rearrangement-positive NSCLC and a PS of 2 to 4 received alectinib orally at 300 mg twice daily. The primary end point of the study was objective response rate (ORR), and the most informative secondary end point was rate of PS improvement. RESULTS: Between September 2014 and December 2015, 18 patients were enrolled in this phase II study. Of those patients, 12, five, and one had a PS of 2, 3, or 4, respectively, whereas four patients had received prior crizotinib treatment. The ORR was 72.2% (90% confidence interval: 52.9-85.8%). The ORR did not differ significantly between patients with a PS of 2 and those with a PS of 3 or higher (58.3% and 100%, respectively [p = 0.114]). The PS improvement rate was 83.3% (90% confidence interval: 64.8-93.1%, p < 0.0001), with the frequency of improvement to a PS of 0 or 1 being 72.2%. The median progression-free survival was 10.1 months. Toxicity was mild, with the frequency of adverse events of grade 3 or higher being low. Neither dose reduction nor withdrawal of alectinib because of toxicity was necessary. CONCLUSIONS: Alectinib is a treatment option for patients with ALK rearrangement-positive NSCLC and a poor PS.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Iwama E, Goto Y, Murakami H, et al. Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401). J Thorac Oncol. 2017. PMID: 28238961. doi:10.1016/j.jtho.2017.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。